Breaking News


Clal Biotechnology Climbs Most in Week on Alzheimer’s Drug Trial

Clal Biotechnology Industries Ltd. (CBI) advanced the most in a week after a unit’s Phase IIb trial of an Alzheimer’s drug showed intermediate “positive” results.

The shares of the investment company gained as much as 2.3 percent, the biggest intraday increase since Jan. 16, and were 1 percent higher at 21.10 shekels as of 11:24 a.m. in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.